JP2000501744A - モルホゲン類似体およびその製法 - Google Patents
モルホゲン類似体およびその製法Info
- Publication number
- JP2000501744A JP2000501744A JP9526303A JP52630397A JP2000501744A JP 2000501744 A JP2000501744 A JP 2000501744A JP 9526303 A JP9526303 A JP 9526303A JP 52630397 A JP52630397 A JP 52630397A JP 2000501744 A JP2000501744 A JP 2000501744A
- Authority
- JP
- Japan
- Prior art keywords
- human
- morphogen
- cells
- hop
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)ヒトOP−1の少なくとも一部分を規定した原子X線結晶学的座標を 内部に配置したメモリと、 (b)メモリと電気的に連絡し、ヒトOP−1の少なくとも一部分を表す三次 元形状を有する分子モデルを生成するプロセスを含むプロセッサと を含む、コンピュータ・システム。 2.プロセッサがさらに、ヒトOP−1の少なくとも一部分を表し、溶媒接触可 能表面を有する分子モデルを生成するプロセスを含む請求の範囲第1項に記載の システム。 3.前記座標が、コンピュータ可読ディスケットに格納される、請求の範囲第1 項に記載のシステム。 4.分子モデルが、ヒトOP−1のフィンガ1領域の少なくとも一部分を表す、 請求の範囲第1項に記載のシステム。 5.分子モデルが、ヒトOP−1のヒール領域の少なくとも一部分を表す、請求 の範囲第1項または第4項に記載のシステム。 6.分子モデルが、ヒトOP−1のフィンガ2領域の少なくとも一部分を表す、 請求の範囲第1項または第4項に記載のシステム。 7.分子モデルが、ヒトOP−1のヒール領域の少なくとも一部分を表す、請求 の範囲第6項に記載のシステム。 8.プロセッサがさらに、ヒトOP−1の三次元形状および溶媒接触可能表面の 少なくとも一部分に対応した、三次元形状および溶媒接触可能表面を有する形態 形成類似体を同定する、請求の範囲第1項に記載のシステム。 9.プロセッサがさらに、修飾後に、ヒトOP−1の水に対する溶解度または安 定性を増強する、座標によって規定された少なくとも1つの候補アミノ酸を同定 する、請求の範囲第1項に記載のシステム。 10.骨形成タンパク質−1(OP−1)様生物活性を有する形態形成類似体の 製法において、 (a)ヒトOP−1の少なくとも一部分を表す三次元形状を規定する分子モデ ルを提供する段階と、 (b)ヒトOP−1の少なくとも一部分を表す三次元形状に対応した三次元形 状を有する候補類似体を同定する段階と、 (c)段階(b)で同定した候補類似体を生成する段階と を含む方法。 11.段階(c)で生成した化合物が、OP−1様生物活性を有するか否かを判 定する段階をさらに含む、請求の範囲第10項に記載の方法。 12.段階(a)で提供される分子モデルが、ヒトOP−1のフィンガ1領域の 少なくとも一部分を表す、請求の範囲第10項に記載の方法。 13.段階(a)で提供される分子モデルが、ヒトOP−1のヒール領域の少な くとも一部分を表すこ、請求の範囲第10項または第12項に記載の方法。 14.段階(a)で提供される分子モデルが、ヒトOP−1のフィンガ2領域の 少なくとも一部分を表す、請求の範囲第10項または第12項に記載の方法。 15.段階(a)で提供される分子モデルが、ヒトOP−1のヒール領域の少な くとも一部分を表す、請求の範囲第14項に 記載の方法。 16.類似体が、類似体の溶媒接触可能表面の周りに間隔をあけて、ヒトOP− 1の溶媒接触可能表面の一部分の周りに間隔をあけて配置された帯電部分に対応 した間隔関係に配置された複数の帯電部分を含む、請求の範囲第10項に記載の 方法。 17.段階(a)および(b)が電子式プロセッサによって実行される、請求の 範囲第10項に記載の方法。 18.段階(a)が、ヒトOP−1の原子座標の少なくとも一部分の表現をコン ピュータ・メモリに格納する段階を含む、請求の範囲第17項に記載の方法。 19.骨形成タンパク質−1(OP−1)によって媒介される生物的効果をモジ ュレートするモルホゲン類似体の製法において、 (a)ヒトOP−1の少なくとも一部分を規定した原子X線結晶学的座標をコ ンピュータ・メモリに提供する段階と、 (b)ヒトOP−1の少なくとも一部分を表す三次元形状および溶媒接触可能 表面を有する分子モデルを、プロセッサを用いて生成する段階と、 (c)さらに、ヒトOP−1の少なくとも一部分の三次元形状および溶媒接触 可能表面に対応した、三次元形状および溶媒接触可能表面を有する候補モルホゲ ン類似体を同定する段階と、 (d)段階(c)で同定された候補モルホゲン類似体を生成する段階と、 (e)段階(d)で生成された候補モルホゲン類似体が、OP−1によって媒 介される生物的効果をモジュレートするか否かを判定する段階と を含む方法。 20.商業的に有用な量の化合物を生成する段階をさらに含む、請求の範囲第1 1項または第19項に記載の方法。 21.前記化合物がペプチドである、請求の範囲第11項または第19項に記載 の方法。 22.OP−1によって媒介される生物的効果をモジュレートする化合物であっ て、請求の範囲第11項または第19項に記載の方法によって生成された化合物 。 23.前記化合物が、ヒトOP−1の生物活性の作動剤として機能する、請求の 範囲第22項に記載の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58955296A | 1996-01-22 | 1996-01-22 | |
US08/589,552 | 1996-01-22 | ||
PCT/US1997/001071 WO1997026277A2 (en) | 1996-01-22 | 1997-01-22 | Morphogen analogs and methods for producing them |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000501744A true JP2000501744A (ja) | 2000-02-15 |
JP2000501744A5 JP2000501744A5 (ja) | 2004-11-11 |
Family
ID=24358486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9526303A Ceased JP2000501744A (ja) | 1996-01-22 | 1997-01-22 | モルホゲン類似体およびその製法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6273598B1 (ja) |
EP (1) | EP0876401B1 (ja) |
JP (1) | JP2000501744A (ja) |
AT (1) | ATE364629T1 (ja) |
AU (1) | AU725295B2 (ja) |
CA (1) | CA2244228A1 (ja) |
DE (1) | DE69737809T2 (ja) |
WO (1) | WO1997026277A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006507804A (ja) * | 2002-06-17 | 2006-03-09 | トラソス インコーポレイテッド | 単一ドメインtdf関連化合物およびその類似体 |
JP2019502674A (ja) * | 2015-08-25 | 2019-01-31 | ヒスタイド アクツィエンゲゼルシャフト | 組織形成誘導用化合物及びその使用 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030185792A1 (en) * | 1996-01-22 | 2003-10-02 | Curis, Inc. | Morphogen analogs of bone morphogenic proteins |
US20040006011A1 (en) * | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
US5922558A (en) * | 1997-09-12 | 1999-07-13 | Lumigen, Inc. | Methods and compositions for generating chemiluminescence with a peroxidase |
DE19831758A1 (de) * | 1998-07-15 | 2000-02-03 | Jerini Bio Tools Gmbh | Ligandenbestimmung für Proteine |
AU2001231154A1 (en) * | 2000-01-24 | 2001-07-31 | Adherex Technologies Inc. | Peptidomimetic modulators of cell adhesion |
ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
US7629309B2 (en) * | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20040005309A1 (en) * | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20030072761A1 (en) * | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
EP1531855A4 (en) * | 2002-01-10 | 2009-07-22 | Osteotrophin Llc | TREATMENT OF BONE DISEASES WITH SKELETTAL ANABOLIKA |
AU2002950183A0 (en) * | 2002-07-12 | 2002-09-12 | The Council Of The Queensland Institute Of Medical Research | Expression of hydrophobic proteins |
US20040093164A1 (en) * | 2002-11-08 | 2004-05-13 | Carlson William D. | Computer system and methods for producing morphogen analogs of human TDF-1 |
US20040215400A1 (en) * | 2003-01-21 | 2004-10-28 | The Trustees Of The University Of Pennsylvania | Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel KcsA |
US20040204862A1 (en) * | 2003-04-11 | 2004-10-14 | Wainer Irving W. | Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
WO2005000308A2 (en) * | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
DE602005020745D1 (de) * | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
CA2561809A1 (en) * | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
EP2789342A1 (en) * | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
AU2012201060B2 (en) * | 2005-09-20 | 2015-01-22 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
ES2537527T3 (es) | 2005-09-20 | 2015-06-09 | Thrasos Innovation, Inc. | Compuestos relacionados con el TDF y análogos de los mismos |
US7659250B2 (en) * | 2005-12-22 | 2010-02-09 | Centocor, Inc. | BMP-7 variant compositions, methods and uses |
JP5100662B2 (ja) * | 2005-12-22 | 2012-12-19 | セントカー・インコーポレーテツド | Bmp−7変異体組成物、方法および使用 |
EP2099523A2 (en) * | 2006-11-13 | 2009-09-16 | ZyStor Therapeutics , Inc. | Methods for treating pompe disease |
US8741840B2 (en) | 2008-02-13 | 2014-06-03 | Washington University | BMP-7 for use in treating neointimal hyperplasia |
US20090291967A1 (en) * | 2008-03-05 | 2009-11-26 | Adherex Technologies, Inc. | Small molecule modulators of cell adhesion |
ES2830350T3 (es) | 2008-05-07 | 2021-06-03 | Biomarin Pharm Inc | Péptidos de dirección lisosómica y usos de los mismos |
ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
US9721070B2 (en) | 2013-12-19 | 2017-08-01 | Chevron Phillips Chemical Company Lp | Selective oligomerization catalysts and methods of identifying same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03500655A (ja) * | 1988-04-08 | 1991-02-14 | ストライカー・コーポレーション | 骨形成デバイス |
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
JPH07500487A (ja) * | 1990-10-18 | 1995-01-19 | ストライカー コーポレイション | 骨形成ペプチド |
JPH08506018A (ja) * | 1993-01-28 | 1996-07-02 | アムジエン・インコーポレーテツド | G−csf類似体組成物及び方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4908773A (en) | 1987-04-06 | 1990-03-13 | Genex Corporation | Computer designed stabilized proteins and method for producing same |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
US5284756A (en) * | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
US5118791A (en) | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5061786A (en) | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
GB8914122D0 (en) * | 1989-06-20 | 1989-08-09 | Wellcome Found | Polypeptide expression |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5688678A (en) * | 1990-05-16 | 1997-11-18 | Genetics Institute, Inc. | DNA encoding and methods for producing BMP-8 proteins |
WO1992001933A1 (en) | 1990-07-20 | 1992-02-06 | E.I. Du Pont De Nemours And Company | Generation of a complete set of structural coordinates of a molecule from a set of partial coordinates |
EP0551440B1 (en) | 1990-09-14 | 2002-12-18 | The Trustees Of The University Of Pennsylvania | Design of bioactive peptides based on immunoglobulin structure |
US5824647A (en) * | 1990-12-12 | 1998-10-20 | Postlethwaite; Arnold E. | Chemotactic wound healing peptides |
DE69223406T2 (de) * | 1991-06-19 | 1998-06-25 | New York Medical College | M-Protein des Influenzavirus als antivirales Mittel |
AU3320193A (en) | 1991-07-22 | 1993-02-23 | Regents Of The University Of California, The | Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex |
JPH05262788A (ja) | 1991-09-03 | 1993-10-12 | Hitachi Chem Co Ltd | ペプチド類、その設計方法及び製造方法並びに受容体上の生理活性ペプチドの結合部位の決定方法 |
US5353236A (en) | 1992-04-23 | 1994-10-04 | The Board Of Trustees Of The Leland Stanford University | High-resolution crystallographic modelling of a macromolecule |
US5322933A (en) | 1992-05-07 | 1994-06-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Crystal structure of TGF-β-2 |
WO1994003601A2 (en) * | 1992-08-03 | 1994-02-17 | New York University | Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan |
CA2153654A1 (en) * | 1993-01-12 | 1994-07-21 | Se-Jin Lee | Growth differentiation factor-5 |
WO1994018236A1 (en) | 1993-02-03 | 1994-08-18 | Amrad Corporation Limited | Receptor-binding determinant from leukaemia inhibitory factor |
US5453937A (en) | 1993-04-28 | 1995-09-26 | Immunex Corporation | Method and system for protein modeling |
US5637480A (en) * | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
US6194544B1 (en) | 1993-07-09 | 2001-02-27 | Smithkline Beecham Corporation | Cyclic semi-random peptide libraries |
GB9317120D0 (en) | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
US5856122A (en) | 1993-08-24 | 1999-01-05 | University Of Alberta | Modification of pertussis toxin |
US5652334A (en) | 1993-09-08 | 1997-07-29 | City Of Hope | Method for design of substances that enhance memory and improve the quality of life |
US5565352A (en) * | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
ATE272719T1 (de) | 1993-11-26 | 2004-08-15 | Lawrence B Hendry | Der entwurf von medikamenten, die in die rezeptor-ligand-dna wechselwirkungen eingreifen |
US6040431A (en) * | 1995-06-07 | 2000-03-21 | Stryker Corporation | Single chain analogs of the TGF-β superfamily (morphons) |
US5932716A (en) * | 1995-07-26 | 1999-08-03 | Creative Biomolecules, Inc. | Morphogen-responsive regulatory elements |
US6677432B1 (en) * | 1998-10-07 | 2004-01-13 | Stryker Corporation | Mutations of the C-terminal portion of TGF-β superfamily proteins |
JP3786533B2 (ja) * | 1998-11-12 | 2006-06-14 | 善彦 西村 | ペプチド及び骨形成促進剤 |
EP1334365B1 (en) * | 2000-11-06 | 2007-02-21 | Thrasos, Inc. | Screening methods for bone morphogenetic mimetics |
-
1997
- 1997-01-22 AU AU22449/97A patent/AU725295B2/en not_active Ceased
- 1997-01-22 AT AT97905604T patent/ATE364629T1/de not_active IP Right Cessation
- 1997-01-22 JP JP9526303A patent/JP2000501744A/ja not_active Ceased
- 1997-01-22 WO PCT/US1997/001071 patent/WO1997026277A2/en active IP Right Grant
- 1997-01-22 US US08/786,284 patent/US6273598B1/en not_active Expired - Lifetime
- 1997-01-22 CA CA002244228A patent/CA2244228A1/en not_active Abandoned
- 1997-01-22 EP EP97905604A patent/EP0876401B1/en not_active Expired - Lifetime
- 1997-01-22 DE DE69737809T patent/DE69737809T2/de not_active Expired - Lifetime
-
2001
- 2001-02-22 US US09/791,946 patent/US20020028453A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03500655A (ja) * | 1988-04-08 | 1991-02-14 | ストライカー・コーポレーション | 骨形成デバイス |
JPH07500487A (ja) * | 1990-10-18 | 1995-01-19 | ストライカー コーポレイション | 骨形成ペプチド |
US5331573A (en) * | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
JPH08506018A (ja) * | 1993-01-28 | 1996-07-02 | アムジエン・インコーポレーテツド | G−csf類似体組成物及び方法 |
Non-Patent Citations (5)
Title |
---|
JPN4007000050, J Mol Biol 244 p.657−658 (1994) * |
JPN6010052329, J Mol Biol 244 p.657−658 (1994) * |
JPN6010052330, Proc Natl Acad Sci USA 93 p.878−883 (1996 Jan) * |
JPNX007000092, Proc Natl Acad Sci USA 93 p.878−883 (1996 Jan) * |
JPNX007000093, Nature 420 p.636 (2002) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006507804A (ja) * | 2002-06-17 | 2006-03-09 | トラソス インコーポレイテッド | 単一ドメインtdf関連化合物およびその類似体 |
JP4654029B2 (ja) * | 2002-06-17 | 2011-03-16 | トラソス インコーポレイテッド | 単一ドメインtdf関連化合物およびその類似体 |
JP2019502674A (ja) * | 2015-08-25 | 2019-01-31 | ヒスタイド アクツィエンゲゼルシャフト | 組織形成誘導用化合物及びその使用 |
JP2022043261A (ja) * | 2015-08-25 | 2022-03-15 | ヒスタイド アクツィエンゲゼルシャフト | 組織形成誘導用化合物及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
AU2244997A (en) | 1997-08-11 |
AU725295B2 (en) | 2000-10-12 |
DE69737809T2 (de) | 2008-02-21 |
DE69737809D1 (de) | 2007-07-26 |
CA2244228A1 (en) | 1997-07-24 |
EP0876401B1 (en) | 2007-06-13 |
US20020028453A1 (en) | 2002-03-07 |
WO1997026277A2 (en) | 1997-07-24 |
EP0876401A2 (en) | 1998-11-11 |
ATE364629T1 (de) | 2007-07-15 |
US6273598B1 (en) | 2001-08-14 |
WO1997026277A3 (en) | 1997-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000501744A (ja) | モルホゲン類似体およびその製法 | |
US8952130B2 (en) | Designer ligands of TGF-β superfamily | |
WO1997026277A9 (en) | Morphogen analogs and methods for producing them | |
AU778998B2 (en) | Cystine knot growth factor mutants | |
KR100353579B1 (ko) | 섬유아세포성장인자의표면고리구조유사체 | |
JP2005287515A (ja) | 形態形成タンパク質を含むTGF−βスーパーファミリー変異体メンバー | |
BR112013003587B1 (pt) | Proteínas osteogênicas projetadas, seus usos, seu método de produção e molécula de ácido nucleico isolada | |
CN102369212A (zh) | 具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体 | |
JPH07103156B2 (ja) | 再生骨髄から同定された骨形成成長ポリペプチド | |
US20040093164A1 (en) | Computer system and methods for producing morphogen analogs of human TDF-1 | |
HUE033025T2 (en) | To induce GDF-5 mutant cartilage tissue | |
KR102404717B1 (ko) | Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드 | |
AU765297B2 (en) | Morphogen analogs and methods for producing them | |
US20190135884A1 (en) | Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating bone and cartilage disease and use thereof | |
US10125168B2 (en) | Synthetic peptide for adjusting balance between presence of type 1 TNF receptor and type 2 TNF receptor and use thereof | |
CA2191321A1 (en) | Gene coding for modified bone morphogenic protein receptor | |
Lee et al. | Development of Refolding Process to Obtain Active Recombinant Human Bone Morphogenetic Protein-2 and its Osteogenic Efficacy on Oral Stem Cells | |
KR20190005239A (ko) | Tgf-베타 슈퍼패밀리의 ab6 패밀리 디자이너 리간드를 포함하는 간질환 치료용 조성물 및 그의 이용 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070416 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070516 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090526 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091217 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100610 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100902 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20110125 |